NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Beren Therapeutics

Beren Therapeutics

Private
Thousand Oaks, CaliforniaHealthcare & Life Scienceshttps://www.berentx.com/

Last Round

VC Round

Jun 10, 2026

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Beren Therapeutics is a biotechnology company that develops cyclodextrin-based therapeutics for conditions characterized by defective cholesterol trafficking, such as Niemann-Pick disease type C.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery

Business Model

B2B2C

Customer Profile

Revenue Share, Government Contracts

AI Layer

Non-AI

Keywords

NLRP3 inhibitorssmall molecule drugspreclinical biotechbrain-penetrant therapiesneuroinflammation therapyALS therapyAlzheimer's disease therapydrug discoveryneurodegenerative diseasesrare disease therapyorphan drug developmentbiopharma partnershipsCNS drug deliveryNew Drug ApplicationNDApublic benefit corporation

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Beren Therapeutics Comparables

Compare Beren Therapeutics with similar companies based on industry and business-model similarity.

Beren Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Ventus Therapeutics
84%
NodThera
81%
Brenig Therapeutics
80%

Beren Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
VC RoundJun 10, 2026
Corporate FundingMay 23, 2023

Key People

Founding team and executive leadership

Jason Camm

Founder & Chief Executive Officer

Founding Team

Aaron Ondrey

Chief Financial Officer

Executive Team

Beren Therapeutics Investors

Notable investors and investment history

Beren Therapeutics investors
InvestorRounds
Hercules CapitalVC Round
Narya CapitalVC Round
GaingelsVC Round
Founders FundVC Round
JIC Venture Growth InvestmentsVC Round
Wellington PartnersVC Round

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 18, 2026

    Grew 24% QoQ, from 83 to 103 employees.

  • Jun 10, 2026

    $135M raised with participation from Founders Fund.

Beren Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Beren Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Beren Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersThousand Oaks, California
Employee Range103
Year Founded2020
Last FundingJun 10, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.